Canadian Investment Regulatory Organization Trade Resumption - CRDL

Canadian Investment Regulatory Organization Trade Resumption - CRDL

Trading resumes in:

Company: Cardiol Therapeutics Inc.

TSX Symbol: CRDL

All Issues: Yes

Resumption (ET): 8:00 AM

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada..

SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Cision View original content: http://www.newswire.ca/en/releases/archive/October2025/20/c1710.html

News Provided by Canada Newswire via QuoteMedia

cardiol therapeuticscrdl:catsx:crdlbiotech investing
CRDL:CA
Cardiol Therapeutics
Sign up to get your FREE

Cardiol Therapeutics Investor Kit

and hear about exciting investment opportunities.
  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics

Heal the heart with innovative science.

Heal the heart with innovative science. Keep Reading...
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen... Keep Reading...
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study... Keep Reading...
Seegnal Inc

Seegnal Expands Deployment of Seegnal's Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, a Leading Israeli Public Medical Center and Global Referral Center

Seegnal Inc. (TSXV: SEGN), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced its deepened partnership with Tel Aviv Sourasky Medical Center ("Sourasky Medical Center"). Israel's second-largest public hospital, Sourasky... Keep Reading...
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private... Keep Reading...
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole... Keep Reading...

Latest News

Cardiol Therapeutics
Sign up to get your FREE

Cardiol Therapeutics Investor Kit

and hear about exciting investment opportunities.
  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

With Step-Out Drilling Continuing, Radisson Demonstrates Meaningful Resource Growth at O'Brien with an Updated Mineral Resource Estimate

Allied Critical Metals Delivers Robust Initial PEA at the Borralha Project

CEO Appointment and NSW Silver Project Acquisition

Closing date for director nominations

Related News

precious metals investing

With Step-Out Drilling Continuing, Radisson Demonstrates Meaningful Resource Growth at O'Brien with an Updated Mineral Resource Estimate

Allied Critical Metals Delivers Robust Initial PEA at the Borralha Project

battery metals investing

CEO Appointment and NSW Silver Project Acquisition

base metals investing

Closing date for director nominations

precious metals investing

New Found Gold Grade Control Drilling Continues to Deliver At-Surface High Grade Gold over Broad Widths at Queensway:

base metals investing

Bold Ventures Signs Agreement to Acquire 6 Key Claims Contiguous to its Joutel Property, Quebec

base metals investing

CORRECTION FROM SOURCE: Video - CEO Clips Bold Ventures Advances Exploration at Burchell and Highlights Ring of Fire